TABLE 3.

The anticancer activities of the title compounds 5a−5w at 5 μg/ml.

Compound	Mortality rate (%)
	PC3	K562	Hela	A549
5a	0	10.03 ± 1.03	3.82 ± 2.64	15.76 ± 1.30
5b	15.53 ± 1.08	0	2.42 ± 1.06	13.65 ± 2.43
5c	0	19.59 ± 1.30	5.98 ± 1.09	13.74 ± 1.76
5d	5.80 ± 2.13	4.73 ± 2.15	11.37 ± 2.15	13.60 ± 2.80
5e	0	5.30 ± 1.16	0.55 ± 2.24	9.23 ± 1.32
5f	4.08 ± 1.67	21.88 ± 2.24	4.23 ± 1.25	12.47 ± 2.35
5g	0	15.52 ± 1.61	2.75 ± 1.60	14.51 ± 2.35
5h	0	10.98 ± 1.14	0	0.22 ± 1.05
5i	3.98 ± 1.22	3.53 ± 1.95	3.58 ± 1.69	15.15 ± 2.64
5j	31.01 ± 1.90	30.99 ± 2.06	25.22 ± 2.37	22.75 ± 2.94
5k	34.20 ± 2.01	37.80 ± 1.95	34.50 ± 1.89	28.50 ± 2.22
5l	54.94 ± 1.51	15.47 ± 1.38	32.20 ± 2.10	37.35 ± 2.00
5m	0	0	0	0
5n	51.71 ± 1.20	17.11 ± 1.52	30.78 ± 1.45	40.78 ± 1.09
5o	50.52 ± 1.22	19.40 ± 1.64	39.54 ± 2.22	38.78 ± 2.26
5p	9.20 ± 1.45	7.30 ± 2.01	20.40 ± 1.70	16.80 ± 3.26
5q	46.11 ± 1.54	31.40 ± 3.12	37.90 ± 3.01	42.42 ± 1.33
5r	55.32 ± 1.35	15.63 ± 0.96	34.65 ± 1.87	41.36 ± 1.51
5s	22.35 ± 1.16	5.28 ± 1.38	25.14 ± 2.03	15.24 ± 1.67
5t	0.37 ± 1.23	12.46 ± 2.26	6.87 ± 2.07	8.41 ± 2.83
5u	31.01 ± 1.64	30.99 ± 1.34	25.22 ± 2.35	22.75 ± 2.90
5v	64.20 ± 1.12	24.00 ± 1.92	48.25 ± 1.17	34.20 ± 2.31
5w	36.20 ± 1.36	35.40 ± 1.83	32.20 ± 2.62	31.80 ± 2.08
Doxorubicin	94.68 ± 1.05	72.81 ± 1.54	80.43 ± 1.36	89.57 ± 2.07